Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia
Portfolio Pulse from
Actinium Pharmaceuticals published positive trial results for Actimab-A + CLAG-M in relapsed/refractory AML patients, showing a median overall survival of 18.4 months and high remission rates, supporting a planned Phase 2/3 trial.
March 18, 2025 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Actinium Pharmaceuticals announced positive results from a trial of Actimab-A + CLAG-M in AML patients, showing significant survival and remission benefits, supporting a Phase 2/3 trial.
The publication of positive trial results in a peer-reviewed journal is likely to boost investor confidence and positively impact Actinium's stock price. The data shows significant survival benefits and high remission rates, which are critical for the success of the upcoming Phase 2/3 trial.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100